- Kidney disease diagnostics group Renalytix welcomed news that a new coverage pathway had been established in the US for medical devices and diagnostics tests.

The Centers for Medicaid & Medicare had set up the Medicare Coverage of Innovative Technology pathway, for Medicare beneficiaries nationwide.

'Having a clear path to national Medicare coverage for innovative products like KidneyIntelX provides a major catalyst to drive the robust research and clinical development programs necessary to address major unmet medical needs such as kidney disease,' president Tom McLain said.

At 9:47am: [LON:RENX] Renalytix Ai PLC share price was 0p at 436p

Story provided by